SignalFDA/Bio

What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?

FDA priority review in MS signals potential accelerated approval catalyst for Roche.

What changed

FDA priority review in MS signals potential accelerated approval catalyst for Roche.

Why it matters

FDA priority review in MS signals potential accelerated approval catalyst for Roche. — impact context not separately stored; see What changed.

Sources